Second-line treatment patterns after first-line immunotherapy in HCC
Автор: VJOncology
Загружено: 2025-07-03
Просмотров: 89
Описание:
Julien Edeline, MD, PhD, Centre Eugene Marquis, Rennes, France, discusses real-world data from the CHIEF cohort, which assessed second-line treatment outcomes in advanced hepatocellular carcinoma (HCC) following first-line sorafenib or atezolizumab and bevacizumab. Access to second-line therapy was more limited post-immunotherapy, though survival with tyrosine kinase inhibitors remained comparable regardless of the first-line regimen. Immunotherapy rechallenge appeared promising, although potentially impacted by selection bias. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
